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CASE REPORT
Submillimeter retinoblastoma 
monitoring following transpupillary 
thermotherapy using hand-held optical 
coherence tomography
Mark McGarrey, Thamolwan Surakiatchanukul and Carol L. Shields*
Abstract 
Background: Precise, submillimeter visualization of retinal microstructures is useful for treatment monitoring of 
retinoblastoma. Herein, we report the use of hand-held optical coherence tomography (HH-OCT) to document a 
nearly-invisible retinoblastoma and monitor tumor response to transpupillary thermotherapy (TTT).
Case presentation: A 3-week-old boy was diagnosed with unilateral familial retinoblastoma in the left eye, clas-
sified as group B, and treated with intravenous chemoreduction. At 13-month follow-up, the tumor in the left eye 
was regressed, and evaluation of the right eye revealed a microscopic, nearly invisible tumor measuring 372 µm in 
thickness and 1.51 mm in basal dimension. The tumor was confirmed on HH-OCT and the diagnosis was changed 
to bilateral familial retinoblastoma. The new tumor was subsequently treated with TTT and after 1 month, the tumor 
regressed to an optically dense scar 166 µm in thickness by HH-OCT. Five months after TTT, the scar was clinically flat 
and measured 73 µm.
Conclusions: HH-OCT has assumed a significant role in the monitoring of retinoblastoma in children. In this case, 
imaging with HH-OCT allowed precise localization of the tumor and submillimeter monitoring of treatment response 
following TTT.
Keywords: Eye, Retina, Retinoblastoma, Chemoreduction, Regression, Transpupillary thermotherapy, Optical 
coherence tomography
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Background
Optical coherence tomography (OCT) is an imag-
ing technology that utilizes the predictable properties 
of light refraction to produce precise cross sectional 
images of the human fundus [1]. Following the popu-
larization of OCT since 1991, OCT technologies includ-
ing spectral domain OCT (SD-OCT) have allowed 
for non-invasive, higher-resolution evaluation of reti-
nal and choroidal microstructures. Subsequent tech-
nological advancements have given rise to hand-held 
OCT (HH-OCT), a portable SD-OCT unit, that can be 
used intra-operatively to image the eyes of children and 
non-cooperative patients [2]. HH-OCT has proven par-
ticularly useful in detection and monitoring of small or 
“invisible” parafoveal retinoblastomas as well as estimat-
ing visual acuity potential in preverbal children [3–5].
Herein, we report a 3-week-old boy with familial ret-
inoblastoma who was detected to have a minimally 
elevated submillimeter tumor, confirmed on HH-OCT. 
Following treatment, documentation of tumor regres-
sion by HH-OCT was important in confirming complete 
tumor response.
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Case presentation
A 3-week-old white male, with a family history of mater-
nal retinoblastoma, presented for clinical evaluation after 
fetal ultrasound revealed a tumor in the left eye (OS). On 
examination, visual acuity was fix and follow in each eye 
and leukocoria OS was noted. Funduscopic evaluation 
right eye (OD) showed no tumor, whereas fundus evalu-
ation OS (Fig.  1a) revealed a macular retinoblastoma 
measuring 10.0  mm in basal dimension and 5.0  mm in 
thickness, classified as group B familial retinoblastoma. 
The patient received six cycles of intravenous chemore-
duction (CRD) using vincristine, etoposide, and carbopl-
atin. Following CRD, the right eye remained normal and 
the left eye (Fig. 1b) showed type III regression, with par-
tial calcification and regressed tumor measuring 6.0 mm 
in basal dimension and 2.1 mm in thickness.
At a 13-month follow-up, a new, minimally elevated 
parafoveal retinoblastoma measuring 1.51  mm in diam-
eter located 6.0 mm temporal to the foveola OD (Fig. 2a) 
was detected by indirect ophthalmoscopy. The left eye 
remained stable with a partially calcified scar. By HH-
OCT, the foveola OD was intact and the tiny parafoveal 
retinoblastoma measured 372  µm in thickness and was 
without subretinal fluid (Fig.  2b). Ultrasonography con-
firmed the tiny retinoblastoma OD of 1.5 mm thickness 
and the regressed calcified retinal scar OS of 2.1  mm 
thickness.
The diagnosis was changed to bilateral familial retino-
blastoma, and the newly-diagnosed retinoblastoma OD 
was treated with transpupillary thermotherapy (TTT) 
using 300 mW power for 4 min with grey-white uptake. 
One month later, retinoblastoma regression was noted 
(Fig.  2c) and HH-OCT (Fig.  2d) revealed thickness 
reduction to 166 µm. Five months after TTT, the scar was 
clinically flat (Fig.  2e), measuring 73  µm on HH-OCT 
(Fig. 2f ). There were no further tumors.
Discussion
Imaging technologies play a significant role in the detec-
tion, diagnosis, and selection of therapeutic options for 
retinoblastoma. Previously, cross-sectional imaging of 
retinoblastoma was only possible with ultrasonography, 
computed tomography, or magnetic resonance imaging. 
These techniques were only able to detect medium to 
large retinoblastoma and provide information on tumor 
configuration, location, size, and extrascleral exten-
sion. However, high resolution HH-OCT has recently 
become available for detection of small retinoblastomas 
as depicted in Table 1 [3–8], and recently even those that 
are sub-millimeter or nearly clinically invisible, as in this 
case.
Fig. 1 Retinoblastoma regression in the left eye after 6 cycles of 
intravenous chemoreduction. The left eye demonstrated a macular 
retinoblastoma (a) measuring 10.0 mm in largest basal dimension 
and 5.0 mm in thickness. After 6 cycles of chemoreduction, the tumor 
(b) showed regression to 6.0 mm in basal dimension and 2.1 mm in 
thickness
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HH-OCT is a portable SD-OCT unit, particularly 
useful for imaging young children and uncooperative 
patients. In 2004, Shields et  al. [9] reported that time 
domain OCT was more sensitive than clinical examina-
tion in detection and monitoring of a variety of macular 
pathology in children such as cystoid macular edema and 
subretinal fluid. Further studies have revealed that HH-
OCT is important for monitoring tumor regression [10], 
detecting subclinical recurrence [6], identifying invisible 
retinoblastoma [4, 5], and elucidating foveal microanat-
omy in children following retinoblastoma treatment [11].
Fig. 2 Retinoblastoma regression documented on hand-held optical coherence tomography (HH-OCT) in the right eye. The initially unaffected 
right eye (a) demonstrated a small retinoblastoma temporal to the fovea of 1.51 mm in basal dimension and 372 µm in thickness (b). One month 
following transpupillary thermotherapy (TTT), the tumor (c) showed regression, confirmed as a (d) hyperreflective scar on OCT of 166 µm thickness. 
At 5 months after TTT, the flat scar (e) measured 73 µm thickness on HH-OCT (f)
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Conclusions
Imaging with HH-OCT was helpful in this case as it con-
firmed tumor presence and allowed for precise, submil-
limeter monitoring of tumor thickness and regression, 
with preservation of foveal microanatomy. We encourage 
all clinicians who manage retinoblastoma to consider the 
use of HH-OCT for best monitoring of even the tiniest 
tumors.
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Table 1 Comparison of published cases of small retinoblastomas documenting tumor detection, regression, or recur-
rence by optical coherence tomography
Reports from peer-reviewed journals in 2014-17 were included
a Dimensions were re-measured after therapy
b Per our interpretation of the published images
Authors Patient demo-
graphics
OCT findings
Tumor diam-
eter (mm)
Tumor thick-
ness (µm)
Distance 
from foveola 
(mm)
Distance 
from optic 
nerve (mm)
Descriptions Machine
Cao et al. [3] 33-month-old 
male
8.0 (6.5)a 4000 (2200)a 0.0 (0.2)a Unspecified 
(0.0)a
Exophytic mass 
draped by 
normal retina
iVue Optovue 
with iStand
9-month-old 
female
12.0 (8.0)a 6300 (3000)a 0.0 (0.5)a Unspecified 
(3.5)a
Exophytic mass 
draped by 
normal retina
7-month-old 
male
11.0 (6.0)a 4000 (2600)a 0.0 (0.0)a Unspecified 
(2.5)a
Exophytic mass 
draped by 
normal retina
Saktanasate et al. 
[4]
2-month-old 
male
Unspecified Unspecified Unspecified Unspecified Ovoid; Outer 
nuclear layer
iVue Optovue
Berry et al. [5] 7-week-old male Unspecified (3 
tumors)
Unspecified Unspecified Unspecified Dome-shaped; 
Outer nuclear, 
outer plexi-
form, and inner 
nuclear layers
InVivoVue, Biop-
tigen
Park et al. [6] 3-week-old 
female
2.10 639 1.85 Unspecified Dome-shaped; 
Outer nuclear 
 layerb
iVue Optovue
Soliman et al. [7] Unspecified Unspecified Unspecified Unspecified Unspecified Ovoidb; Inner 
nuclear layer
Bioptigen Envisu 
C2200/C2300
Yarovaya et al. [8] 3-week-old 
female
2.75 792 0.62 Unspecified Dome-shapedb; 
Outer retinal 
 layerb
iVue Optovue
Current report 3-week-old male 1.51 372 6.0 9.0 Dome-shaped; 
Inner retinal 
layer
iVue Optovue
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